newsfilter
← Latest News
ACCESS Newswire·

Xenetic Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Ongoing preclinical studies with data expected before year endFocus on demonstration of DNase-based oncology program in clinical proof-of-concept studies in multiple indicationsEnded the quarter with $7.3 million of cash